Nurix Therapeutics, Inc. (NRIX) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended August 31, 2025. Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation for cancer and inflammatory diseases. The company leverages its proprietary DEL-AI platform to discover drug candidates. Key programs include bexobrutideg (NX-5948), zelebrudomide (NX-2127), and NX-1607. The company has strategic collaborations with Gilead, Sanofi, and Pfizer (via Seagen).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Aug 31, 2025 | Nine Months Ended Aug 31, 2025 | Nine Months Ended Aug 31, 2024 |
|---|---|---|---|
| Total Revenue | $7,894 | $70,403 | $41,265 |
| Net Loss | $(86,421) | $(186,236) | $(135,020) |
| Net Loss Per Share (Basic/Diluted) | $(1.03) | $(2.22) | $(2.13) |
| Research & Development Expenses | $86,120 | $233,879 | $154,408 |
| General & Administrative Expenses | $13,159 | $39,095 | $35,227 |
| Cash, Cash Equivalents & Marketable Securities | $428,838 (as of Aug 31, 2025) | N/A | |
| Accumulated Deficit | $(925,005) (as of Aug 31, 2025) | N/A |
Material Changes vs. Prior Period
- Revenue: Total revenue for the nine months ended August 31, 2025, increased by $29.1 million (71%) compared to the same period in 2024. This increase was primarily driven by $30.0 million in license revenue from Sanofi License Extensions recognized in the current period. Collaboration revenue decreased slightly by $0.9 million year-over-year due to the conclusion of initial research terms with Gilead and Sanofi, partially offset by increased revenue from Pfizer.
- Expenses: Research and development (R&D) expenses increased by $79.5 million (52%) for the nine-month period, driven by accelerated clinical trial enrollment for bexobrutideg and zelebrudomide, and increased contract research costs. General and administrative expenses increased by $3.9 million (11%) due to higher headcount and consulting costs.
- Liquidity: Cash, cash equivalents, and marketable securities decreased from $609.6 million as of November 30, 2024, to $428.8 million as of August 31, 2025. Net cash used in operating activities was $181.6 million for the nine months ended August 31, 2025, compared to $123.8 million in the prior year period.
Guidance, Outlook, and Risks
- Outlook: Management believes existing cash resources are sufficient to fund operations for at least the next 12 months. The company expects to incur significant losses for the foreseeable future as it advances clinical trials and expands its pipeline.
- Clinical Progress:
- Bexobrutideg (NX-5948): Phase 1a/1b ongoing; Phase 2 initiation expected in 2025. Received Fast Track and Orphan Drug Designations for CLL/SLL and Waldenström macroglobulinemia.
- Zelebrudomide (NX-2127): Phase 1a/1b ongoing; FDA lifted partial clinical hold in March 2024; enrollment reinitiated with new drug product.
- NX-1607: Phase 1a/1b ongoing for immuno-oncology indications.
- Risks:
- Capital Needs: The company will require substantial additional funding to complete development and commercialization. Failure to raise capital could force delays or termination of programs.
- Development Risk: Drug candidates are in early clinical stages with high failure rates. Preclinical and early clinical results may not predict later-stage success.
- Collaboration Dependence: Revenue relies heavily on collaborations with Gilead, Sanofi, and Pfizer. Termination or failure of these partnerships would materially harm the business.
- Regulatory & Manufacturing: Risks include delays in regulatory approvals, manufacturing supply chain disruptions (including potential tariffs on Chinese manufacturers), and reliance on third-party CMOs.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $428.8 million cash position against the projected burn rate of approximately $181.6 million per nine months.
- Revenue Recognition: Confirm the sustainability of the $30.0 million license revenue from Sanofi, which was a one-time event in the current period, versus recurring collaboration revenue.
- Clinical Milestones: Monitor the initiation of the Phase 2 trial for bexobrutideg in 2025 and the safety/efficacy data from ongoing Phase 1 trials.
- Collaboration Terms: Review the remaining potential milestone payments ($6.1 billion total) and the conditions required to trigger them under agreements with Gilead, Sanofi, and Pfizer.
- Manufacturing Supply Chain: Assess the impact of recent U.S. tariffs on goods from China, where some third-party manufacturers are located, on future drug supply costs and availability.